{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:14:17Z","timestamp":1782623657250,"version":"3.54.5"},"reference-count":125,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.<\/jats:p>","DOI":"10.1055\/s-0043-1776910","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T23:52:15Z","timestamp":1705449135000},"page":"817-828","source":"Crossref","is-referenced-by-count":15,"title":["Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome"],"prefix":"10.1055","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5456-3488","authenticated-orcid":false,"given":"Rodrigo","family":"Aguirre del-Pino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands"},{"name":"Division of Rheumatology, A Coru\u00f1a University Hospital (CHUAC), Galicia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory C.","family":"Monahan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands"},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W.J.","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Eikenboom","sequence":"additional","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center (LUMC), Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda M.","family":"Steup-Beekman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands"},{"name":"Department of Rheumatology, Haaglanden Medical Center, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"S Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0042-1744363","article-title":"Testing for lupus anticoagulants","volume":"48","author":"G W Moore","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"R Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11926-021-01051-5","article-title":"An update on antiphospholipid syndrome","volume":"23","author":"E Xourgia","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/antib5020015","article-title":"Antiphospholipid antibodies: their origin and development","volume":"5","author":"K J Lackner","year":"2016","journal-title":"Antibodies (Basel)"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"B Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/bloodadvances.2020001557","article-title":"Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors","volume":"4","author":"N Abdel-Wahab","year":"2020","journal-title":"Blood Adv"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1445-5994.1990.tb01025.x","article-title":"Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population","volume":"20","author":"W Shi","year":"1990","journal-title":"Aust N Z J Med"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0038-1648840","article-title":"Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects","volume":"72","author":"P Vila","year":"1994","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1646452","article-title":"The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study","volume":"66","author":"A A Long","year":"1991","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-112-9-682","article-title":"Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance","volume":"112","author":"P E Love","year":"1990","journal-title":"Ann Intern Med"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/jth.15518","article-title":"Single or triple positivity for antiphospholipid antibodies in \u201ccarriers\u201d or symptomatic patients: Untangling the knot","volume":"19","author":"D Bertin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-019-0869-y","article-title":"Genetics of antiphospholipid syndrome","volume":"21","author":"L Ortiz-Fern\u00e1ndez","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0961203312440348","article-title":"Association between the valine\/leucine247 polymorphism of \u03b22-glycoprotein I and susceptibility to anti-phospholipid syndrome: a meta-analysis","volume":"21","author":"Y H Lee","year":"2012","journal-title":"Lupus"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"G Canaud","year":"2014","journal-title":"N Engl J Med"},{"issue":"01","key":"ref16","first-page":"115","article-title":"Antiphospholipid antibodies in a large population-based cohort: genome-wide associations and effects on monocyte gene expression","volume":"116","author":"N M\u00fcller-Calleja","year":"2016","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"M Galli","year":"2003","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12016-008-8103-0","article-title":"Infections and the antiphospholipid syndrome","volume":"36","author":"M Garc\u00eda-Carrasco","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0961203317731532","article-title":"Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis","volume":"27","author":"N Abdel-Wahab","year":"2018","journal-title":"Lupus"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.chom.2019.05.003","article-title":"Pathogenic autoreactive T and B cells cross-react with mimotopes expressed by a common human gut commensal to trigger autoimmunity","volume":"26","author":"W E Ruff","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/01.CIR.97.22.2195","article-title":"Antiphospholipid syndrome in the elderly: caution","volume":"97","author":"J C Piette","year":"1998","journal-title":"Circulation"},{"issue":"08","key":"ref22","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.3390\/ijms23084151","article-title":"Antiphospholipid antibodies and lipids in hematological malignancies","volume":"23","author":"S G Barreno-Rocha","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"A Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"J Y Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"G Ruiz-Irastorza","year":"2004","journal-title":"Arch Intern Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"932181","DOI":"10.3389\/fimmu.2022.932181","article-title":"Relationship between gender differences and clinical outcome in patients with the antiphospholipid syndrome","volume":"13","author":"S Truglia","year":"2022","journal-title":"Front Immunol"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1055\/s-0034-1390003","article-title":"Thrombotic risk in the antiphospholipid syndrome","volume":"40","author":"W Lim","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"ref28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"P G de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"22","key":"ref29","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)","volume":"125","author":"J Gebhart","year":"2015","journal-title":"Blood"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"M G Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays","volume":"16","author":"W Chayoua","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"V Pengo","year":"2005","journal-title":"Thromb Haemost"},{"issue":"21","key":"ref33","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"D Garcia","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"G RV Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"e0178889","DOI":"10.1371\/journal.pone.0178889","article-title":"Incidence of thromboembolic events in asymptomatic carriers of IgA anti \u00df2 glycoprotein-I antibodies","volume":"12","author":"C Tortosa","year":"2017","journal-title":"PLoS One"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1538-7836.2007.02532.x","article-title":"Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study","volume":"5","author":"N Bizzaro","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/keab414","article-title":"\u2018Non-criteria antiphospholipid antibodies\u2019: bridging the gap between seropositive and seronegative antiphospholipid syndrome","volume":"61","author":"S Truglia","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"102689","DOI":"10.1016\/j.autrev.2020.102689","article-title":"\u201cNon-criteria\u201d antiphospholipid syndrome: a nomenclature proposal","volume":"19","author":"G Pires da Rosa","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/keu307","article-title":"The global anti-phospholipid syndrome score in primary APS","volume":"54","author":"S Sciascia","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/rheumatology\/kev238","article-title":"Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study","volume":"54","author":"S Zuily","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0961203310395052","article-title":"Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (II): thrombocytopenia and skin manifestations","volume":"20","author":"R Cervera","year":"2011","journal-title":"Lupus"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/acr.23584","article-title":"The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository","volume":"71","author":"O Unlu","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"101463","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"L R Sammaritano","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1001\/archinte.1986.00360230069012","article-title":"Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test","volume":"146","author":"E N Harris","year":"1986","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12016-021-08862-5","article-title":"Risk factors for the development of the disease in antiphospholipid antibodies carriers: a long-term follow-up study","volume":"62","author":"R D Pablo","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"16","key":"ref46","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2010-05-283507","article-title":"Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study","volume":"116","author":"L Comellas-Kirkerup","year":"2010","journal-title":"Blood"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study","volume":"15","author":"R Hisada","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000595","article-title":"Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome","volume":"31","author":"A P Vreede","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.3390\/ijms21114120","article-title":"Antiphospholipid antibodies and autoimmune haemolytic anaemia: a systematic review and meta-analysis","volume":"21","author":"P RJ Ames","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/qjmed\/93.8.523","article-title":"Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome","volume":"93","author":"M G Tektonidou","year":"2000","journal-title":"QJM"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"J Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"ref52","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases","volume":"19","author":"Y Shen","year":"2010","journal-title":"Lupus"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"M G Tektonidou","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"9533","key":"ref54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0140-6736(06)69110-1","article-title":"Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis","volume":"368","author":"S McRae","year":"2006","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"895098","DOI":"10.3389\/fcvm.2022.895098","article-title":"Sex differences in clinical characteristics and prognosis in primary thrombotic antiphospholipid syndrome","volume":"9","author":"Y Huang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","article-title":"Risk factors for arterial thrombosis in antiphospholipid syndrome","volume":"133","author":"A Matyja-Bednarczyk","year":"2014","journal-title":"Thromb Res"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"S Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11926-007-0004-3","article-title":"Neurologic manifestations of the antiphospholipid syndrome","volume":"9","author":"J F Roldan","year":"2007","journal-title":"Curr Rheumatol Rep"},{"issue":"14","key":"ref59","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/0961203312458469","article-title":"Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome","volume":"21","author":"Y Fujieda","year":"2012","journal-title":"Lupus"},{"issue":"11","key":"ref60","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/acr.24720","article-title":"Ethnicity and antiphospholipid syndrome in Israel","volume":"74","author":"S Niznik","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"ref61","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1111\/1756-185X.13117","article-title":"Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter cross-sectional study","volume":"21","author":"V Manzano-Gamero","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-019-01836-7","article-title":"Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience","volume":"48","author":"G Abu-Zeinah","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"621270","DOI":"10.1155\/2014\/621270","article-title":"Cardiovascular risk factors in the antiphospholipid syndrome","volume":"2014","author":"F F da Silva","year":"2014","journal-title":"J Immunol Res"},{"issue":"01","key":"ref64","first-page":"36","article-title":"Fatores de risco tradicionais para doen\u00e7a cardiovascular na s\u00edndrome antifosfol\u00edpide 36 prim\u00e1ria comparada \u00e0 secund\u00e1ria: um estudo de 96 pacientes","volume":"35","author":"A R Ribeiro","year":"2010","journal-title":"Acta Reumatol Port"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/107602960200800205","article-title":"Are antiphospholipid antibodies an independent risk factor for atherosclerosis?","volume":"8","author":"F Bilora","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/rheumatology\/keaa542","article-title":"Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study","volume":"60","author":"Y Ogata","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"ref67","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1177\/09612033221114275","article-title":"Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients","volume":"31","author":"C M Yelnik","year":"2022","journal-title":"Lupus"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.88.5.2149","article-title":"Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults","volume":"88","author":"D S Celermajer","year":"1993","journal-title":"Circulation"},{"issue":"14","key":"ref69","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"P Mustonen","year":"2014","journal-title":"Lupus"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"981519","DOI":"10.1155\/2012\/981519","article-title":"Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke","volume":"2012","author":"J F de Carvalho","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"06","key":"ref71","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/1076029618755946","article-title":"Identifying additional risk factors for thrombosis and pregnancy morbidities among antiphospholipid antibodies carriers","volume":"24","author":"Y Zuo","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0121-8123(12)70016-6","article-title":"S\u00edndrome antifosfol\u00edpido: descripci\u00f3n de una cohorte de pacientes colombianos y evaluaci\u00f3n de los factores de riesgo para trombosis","volume":"19","author":"M Mesa","year":"2012","journal-title":"Revista Colombiana de Reumatologia"},{"issue":"05","key":"ref73","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/1076029617727859","article-title":"Impact of classical risk factors for arterial or venous thrombosis in patients with antiphospholipid syndrome","volume":"24","author":"D Navarro-Carpentieri","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2018.09.010","article-title":"The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies","volume":"278","author":"M ND Di Minno","year":"2018","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/1744666X.2019.1543025","article-title":"Clinical profiles and risk assessment in patients with antiphospholipid antibodies","volume":"15","author":"M Kato","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/rheumatology\/keh581","article-title":"Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome","volume":"44","author":"S Jim\u00e9nez","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"08","key":"ref77","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1093\/rheumatology\/keab882","article-title":"Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3\u2009year prospective study","volume":"61","author":"G Evangelatos","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/07853890.2014.959559","article-title":"Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies","volume":"46","author":"P Ambrosino","year":"2014","journal-title":"Ann Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"102813","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis","volume":"128","author":"M G Tektonidou","year":"2022","journal-title":"J Autoimmun"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"T Kolitz","year":"2019","journal-title":"Front Immunol"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/RHU.0000000000001824","article-title":"Systemic lupus erythematosus and antiphospholipid antibody syndrome as risk factors for acute coronary syndrome in young patients: analysis of the National Inpatient Sample","volume":"28","author":"M Whittier","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"e000579","DOI":"10.1136\/lupus-2021-000579","article-title":"Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus","volume":"8","author":"E Bolla","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"02","key":"ref83","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.rdc.2005.01.008","article-title":"Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto Lupus Clinic experience","volume":"31","author":"M B Urowitz","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"issue":"09","key":"ref84","first-page":"1715","article-title":"Lupus and thrombosis","volume":"33","author":"D Erkan","year":"2006","journal-title":"J Rheumatol"},{"issue":"11","key":"ref85","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/art.39758","article-title":"Brief report: trends in hospitalizations due to acute coronary syndromes and stroke in patients with systemic lupus erythematosus, 1996 to 2012","volume":"68","author":"M G Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"R Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"ref87","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/0961203309106831","article-title":"The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe","volume":"18","author":"R Cervera","year":"2009","journal-title":"Lupus"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0198-8859(02)00789-9","article-title":"Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus","volume":"64","author":"A Amoroso","year":"2003","journal-title":"Hum Immunol"},{"issue":"05","key":"ref89","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/096120339700600510","article-title":"Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus \u2013 a meta-analysis","volume":"6","author":"D G Wahl","year":"1997","journal-title":"Lupus"},{"issue":"12","key":"ref90","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/0961203320950477","article-title":"Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality","volume":"29","author":"L Riancho-Zarrabeitia","year":"2020","journal-title":"Lupus"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"102355","DOI":"10.1016\/j.jaut.2019.102355","article-title":"In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation","volume":"107","author":"I A Andrianova","year":"2020","journal-title":"J Autoimmun"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1191\/0961203304lu1006oa","article-title":"Antiphospholipid antibodies in primary Sj\u00f6gren's syndrome: prevalence and clinical significance in a series of 74 patients","volume":"13","author":"A L Fauchais","year":"2004","journal-title":"Lupus"},{"issue":"05","key":"ref93","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semarthrit.2016.10.004","article-title":"Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis","volume":"46","author":"M Merashli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11926-006-0049-8","article-title":"The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis","volume":"8","author":"E Olech","year":"2006","journal-title":"Curr Rheumatol Rep"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2133.1994.tb08456.x","article-title":"Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations","volume":"131","author":"P Wolf","year":"1994","journal-title":"Br J Dermatol"},{"issue":"10","key":"ref96","doi-asserted-by":"crossref","first-page":"480","DOI":"10.20452\/pamw.1415","article-title":"Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity","volume":"122","author":"R Jeleniewicz","year":"2012","journal-title":"Pol Arch Med Wewn"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/096120330000900108","article-title":"Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel overlap syndrome","volume":"9","author":"Y Sherer","year":"2000","journal-title":"Lupus"},{"issue":"24","key":"ref98","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"M Petri","year":"2005","journal-title":"N Engl J Med"},{"issue":"04","key":"ref99","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00001721-199606000-00011","article-title":"Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies","volume":"7","author":"A Girolami","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"11","key":"ref100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"R T Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref101","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.contraception.2004.07.009","article-title":"Progestogen-only contraception in women at high risk of venous thromboembolism","volume":"70","author":"J Conard","year":"2004","journal-title":"Contraception"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-021-01006-w","article-title":"Which hormones and contraception for women with APS? Exogenous hormone use in women with APS","volume":"23","author":"L R Sammaritano","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"ref103","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1177\/0961203314528062","article-title":"Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"L R Sammaritano","year":"2014","journal-title":"Lupus"},{"issue":"04","key":"ref104","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-10-1038","article-title":"A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones","volume":"164","author":"H Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JBM.S166780","article-title":"Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy","volume":"10","author":"Z Goldstein","year":"2019","journal-title":"J Blood Med"},{"issue":"02","key":"ref106","first-page":"55","article-title":"Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals","volume":"2","author":"J D Weinand","year":"2015","journal-title":"J Clin Transl Endocrinol"},{"issue":"04","key":"ref107","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1089\/lgbt.2018.0099","article-title":"Spontaneous superior ophthalmic vein thrombosis in a transgender man with systemic lupus erythematosus","volume":"6","author":"J Park","year":"2019","journal-title":"LGBT Health"},{"issue":"05","key":"ref108","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","article-title":"Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review","volume":"122","author":"D Garcia","year":"2013","journal-title":"Blood"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"843718","DOI":"10.3389\/fimmu.2022.843718","article-title":"Patterns of recurrent thrombosis in primary antiphospholipid syndrome-multicenter, real-life long-term follow-up","volume":"13","author":"S Niznik","year":"2022","journal-title":"Front Immunol"},{"issue":"04","key":"ref110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.autrev.2009.04.001","article-title":"Antiphospholipid antibodies and malignancies","volume":"9","author":"A Tincani","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"04","key":"ref111","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.thj.6200377","article-title":"Antiphospholipid antibodies in lymphoma: prevalence and clinical significance","volume":"5","author":"S Pusterla","year":"2004","journal-title":"Hematol J"},{"issue":"01","key":"ref112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.hoc.2007.10.004","article-title":"Antiphospholipid antibodies and malignancy","volume":"22","author":"C Pham","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0961203303lu328oa","article-title":"High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis","volume":"12","author":"K H Yoon","year":"2003","journal-title":"Lupus"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-0041-1729856","article-title":"Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature","volume":"48","author":"E J Favaloro","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"102592","DOI":"10.1016\/j.jaut.2020.102592","article-title":"The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - a systematic review of the literature","volume":"117","author":"L Novelli","year":"2021","journal-title":"J Autoimmun"},{"issue":"01","key":"ref116","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-020-02335-w","article-title":"Lupus anticoagulant and mortality in patients hospitalized for COVID-19","volume":"52","author":"C Gazzaruso","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref117","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0041-1728832","article-title":"COVID-19 and antiphospholipid antibodies: time for a reality check?","volume":"48","author":"E J Favaloro","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref118","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MBC.0000000000000963","article-title":"Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit","volume":"32","author":"A Hamad\u00e9","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"02","key":"ref119","doi-asserted-by":"crossref","first-page":"102729","DOI":"10.1016\/j.autrev.2020.102729","article-title":"Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward","volume":"20","author":"A Le Joncour","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"09","key":"ref120","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/ijms22094689","article-title":"Extracellular vesicles and antiphospholipid syndrome: state-of-the-art and future challenges","volume":"22","author":"U \u0160tok","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref121","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.semarthrit.2017.10.007","article-title":"Vitamin D and antiphospholipid syndrome: a retrospective cohort study and meta-analysis","volume":"47","author":"L Riancho-Zarrabeitia","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"07","key":"ref122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203312446386","article-title":"Vitamin D and antiphospholipid syndrome","volume":"21","author":"L Andreoli","year":"2012","journal-title":"Lupus"},{"issue":"02","key":"ref123","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.atherosclerosis.2011.08.009","article-title":"Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites","volume":"219","author":"J Be\u0142towski","year":"2011","journal-title":"Atherosclerosis"},{"issue":"09","key":"ref124","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/09612033221101731","article-title":"Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome","volume":"31","author":"A P Rosa Dos Santos","year":"2022","journal-title":"Lupus"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"102311","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: pathogenetic, clinical and therapeutic implications","volume":"104","author":"E Xourgia","year":"2019","journal-title":"J Autoimmun"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1776910.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:28:20Z","timestamp":1730802500000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1776910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":125,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1776910","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}